Activatable antibodies that bind epidermal growth factor receptor and methods thereof
The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
1. A method of treating or delaying the progression of a cancer associated with aberrant expression or activity of Epidermal Growth Factor Receptor (EGFR) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an activatable antibody that in an activated state binds EGFR, wherein said activatable antibody comprises:
(a) an antibody or an antigen binding fragment thereof (AB) that specifically binds to EGFR, wherein the AB comprises:
(i) a heavy chain comprising:
(1) an amino acid sequence with at least one of the following amino acid sequence features: (1) a glutamine residue at the position corresponding to position 88 of SEQ ID NO: 26, SEQ ID NO: 30, and SEQ ID NO: 34, and (2) an alanine residue at the position corresponding to position 299 of SEQ ID NO: 26, SEQ ID NO: 30, and SEQ ID NO: 34, and
(2) heavy chain complementarity determining regions (HCDRs), wherein the HCDRs are the HCDRs of a heavy chain amino acid sequence selected from the group consisting of: SEQ ID NO: 26, SEQ ID NO: 30, and SEQ ID NO: 34, and
(ii) a light chain comprising light chain complementarity determining regions (LCDRs), wherein the LCDRs are the LCDRs of light chain amino acid sequence SEQ ID NO: 68;
(b) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB of the activatable antibody in an uncleaved state to EGFR, wherein the MM comprises the amino acid sequence CISPRGCPDGPYVMY (SEQ ID NO:14); and
(c) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease and wherein the CM comprises the amino acid sequence LSGRSDNH (SEQ ID NO: 13),
wherein the activatable antibody in the uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: MM-CM-AB or AB-CM-MM.
2. The method of claim 1 , wherein the cancer is breast cancer, colorectal cancer, gastric cancer, glioblastoma, head and neck cancer, lung cancer, ovarian cancer, endometrial cancer, pancreatic cancer, prostate cancer, renal cancer, sarcoma, skin cancer, triple-negative breast cancer, esophageal cancer, non-small cell lung cancer, osteosarcoma, squamous cell cancer, basal cell carcinoma, or melanoma.
3. The method of claim 1 , the AB is conjugated to an agent.
4. The method of claim 3 , wherein the agent has one or more of the characteristics selected from the group consisting of:
(a) the agent is a toxin or fragment thereof,
(b) the agent is a dolastatin or a derivative thereof,
(c) the agent is an auristatin or derivative thereof,
(d) the agent is auristatin E or a derivative thereof,
(e) the agent is monomethyl auristatin E (MMAE),
(f) the agent is a maytansinoid or a derivative thereof,
(g) the agent is DM1,
(h) the agent is DM4,
(i) the agent is a duocarmycin or derivative thereof,
(j) the agent is a calicheamicin or derivative thereof,
(k) the agent is a detectable moiety, and
(l) the agent is a diagnostic agent.
5. The method of claim 3 , wherein the agent is conjugated to the AB via a linker.
6. The method of claim 5 , wherein the linker is a cleavable linker.
7. The method of claim 1 , wherein the AB thereof is selected from the group consisting of a Fab fragment, a F(ab′) 2 fragment, a scFv, and a scAb.
8. The method of claim 1 , wherein the HCDRs of the AB comprise the amino acid sequences NYGVH (SEQ ID NO: 71), VIWSGGNTDYNTPFTS (SEQ ID NO: 72), and ALTYYDYEFAY (SEQ ID NO: 73); and
the LCDRs of the AB comprise the amino acid sequences RASQSIGTNIH (SEQ ID NO: 74, YASESIS (SEQ ID NO: 75), and QQNNNWPTT (SEQ ID NO: 76).
9. The method of claim 1 , wherein the AB comprises:
(i) a heavy chain variable region, wherein the heavy chain variable region is the heavy chain variable region of a heavy chain amino acid sequence selected from the group consisting of SEQ ID NO: 26 and SEQ ID NO: 34,
(ii) a light chain variable region, wherein the light chain variable region is the light chain variable region of light chain amino acid sequence SEQ ID NO: 68.
10. The method of claim 1 , wherein the activatable antibody comprises a first linking peptide (LP1) and a second linking peptide (LP2), and wherein the activatable antibody in an uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM.
11. The method of claim 10 , wherein at least one of LP1 or LP2 comprises an amino acid sequence selected from the group consisting of (GS) n , (GGS) n , (GSGGS) n (SEQ ID NO: 15) and (GGGS) n (SEQ ID NO: 16), where n is an integer of at least one.
12. The method of claim 10 , wherein at least one of LP1 or LP2 comprises an amino acid sequence selected from the group consisting of GGSG (SEQ ID NO: 17), GGSGG (SEQ ID NO: 18), GSGSG (SEQ ID NO: 19), GSGGG (SEQ ID NO: 20), GGGSG (SEQ ID NO: 21), GSSSG (SEQ ID NO: 22), GSSGGSGGSGGSG (SEQ ID NO: 23), GSSGT (SEQ ID NO: 24), and GSSG (SEQ ID NO: 37).
13. The method of claim 10 , wherein LP1 comprises the amino acid sequence GSSGGSGGSGGSG (SEQ ID NO: 23) and LP2 comprises the amino acid sequence GSSGT (SEQ ID NO: 24) or GSSG (SEQ ID NO: 37).
14. The method of claim 1 , wherein the activatable antibody in an uncleaved state comprises a spacer, wherein the spacer is joined directly to the MM and has the structural arrangement from N-terminus to C-terminus of spacer-MM-CM-AB.
15. The method of claim 14 , wherein the spacer comprises the amino acid sequence QGQSGQ (SEQ ID NO: 38).
16. The method of claim 1 , wherein the activatable antibody comprises a first linking peptide (LP1) and a second linking peptide (LP2) such that the activatable antibody in an uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM, wherein LP1 comprises the amino acid sequence GSSGGSGGSGGSG (SEQ ID NO: 23) and LP2 comprises the amino acid sequence GSSGT (SEQ ID NO: 24) or GSSG (SEQ ID NO: 37), and wherein the AB comprises a heavy chain amino acid sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 26, SEQ ID NO: 30, and SEQ ID NO: 34, and a light chain amino acid sequence comprising the amino acid sequence of SEQ ID NO: 68.